Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PMC
2276
DELISTED
PharMerica Corporation
PMC
| $1.95M | ﹤0.01% |
+74,389
| New | +$1.83M |
|
|
JMBA
2277
DELISTED
Jamba, Inc.
JMBA
| $1.95M | ﹤0.01% |
250,060
+92,475
| +59% | +$724K |
|
2278
Kilroy Realty
KRC
$4.25B
| $1.95M | ﹤0.01% |
25,900
-149,700
| -85% | -$11M |
|
|
QUMU
2279
DELISTED
Qumu Corp.
QUMU
| $1.94M | ﹤0.01% |
665,412
+23,312
| +4% | +$65.6K |
|
|
TAX
2280
DELISTED
Liberty Tax, Inc. Class A
TAX
| $1.94M | ﹤0.01% |
149,500
-41,252
| -22% | -$572K |
|
2281
Rocky Brands
RCKY
$355M
| $1.94M | ﹤0.01% |
143,900
+18,700
| +15% | +$251K |
|
2282
Aecom
ACM
$8.15B
| $1.93M | ﹤0.01% |
59,744
-332,933
| -85% | -$11M |
|
2283
Crown Crafts
CRWS
$30.7M
| $1.93M | ﹤0.01% |
278,000
+9,200
| +3% | +$69.5K |
|
2284
FTI Consulting
FCN
$4.19B
| $1.93M | ﹤0.01% |
55,200
-190,100
| -77% | -$6.94M |
|
2285
Protalix BioTherapeutics
PLX
$183M
| $1.93M | ﹤0.01% |
230,080
+37,330
| +19% | +$350K |
|
2286
Frontline
FRO
$9.2B
| $1.92M | ﹤0.01% |
+335,700
| New | +$2.06M |
|
2287
Angi Inc
ANGI
$193M
| $1.92M | ﹤0.01% |
15,030
+10,170
| +209% | +$1M |
|
2288
Citi Trends
CTRN
$611M
| $1.92M | ﹤0.01% |
90,500
-4,100
| -4% | -$77.3K |
|
|
HMLP
2289
DELISTED
HOEGH LNG PARTNERS LP
HMLP
| $1.92M | ﹤0.01% |
100,267
-11,830
| -11% | -$229K |
|
|
WEB
2290
DELISTED
Web.com Group, Inc.
WEB
| $1.92M | ﹤0.01% |
75,900
+45,500
| +150% | +$963K |
|
2291
EVI Industries
EVI
$217M
| $1.91M | ﹤0.01% |
70,500
-11,100
| -14% | -$257K |
|
|
AL
2292
DELISTED
Air Lease Corp
AL
| $1.9M | ﹤0.01% |
+50,910
| New | +$1.9M |
|
2293
Midland States Bancorp
MSBI
$693M
| $1.9M | ﹤0.01% |
56,722
+28,222
| +99% | +$964K |
|
2294
Commerce Bancshares
CBSH
$8.65B
| $1.9M | ﹤0.01% |
51,772
-53,211
| -51% | -$1.9M |
|
|
OSB
2295
DELISTED
Norbord Inc.
OSB
| $1.89M | ﹤0.01% |
60,800
-40,000
| -40% | -$1.18M |
|
2296
LCNB Corp
LCNB
$284M
| $1.88M | ﹤0.01% |
94,124
-405
| -0.4% | -$8.55K |
|
|
AGEN
2297
Agenus
AGEN
$332M
| $1.88M | ﹤0.01% |
24,447
+23,840
| +3,928% | +$1.68M |
|
2298
TAT Technologies
TATT
$537M
| $1.86M | ﹤0.01% |
182,200
+30,400
| +20% | +$327K |
|
|
TGE
2299
DELISTED
Tallgrass Energy, LP Class A Shares
TGE
| $1.85M | ﹤0.01% |
72,912
-131,733
| -64% | -$3.47M |
|
|
ORM
2300
DELISTED
Owens Realty Mortgage, Inc.
ORM
| $1.85M | ﹤0.01% |
108,995
+16,930
| +18% | +$291K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.